Evidence map›Paper›PMID 28684402›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

BRAF

Taral R Lunavat, Lesley Cheng, Berglind O Einarsdottir, Roger Olofsson Bagge, Somsundar Veppil Muralidharan, Robyn A Sharples, Cecilia Lässer, Yong Song Gho, Andrew F Hill, Jonas A Nilsson and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Prospects and challenges of tissue-derived extracellular vesicles.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Research advances of tissue-derived extracellular vesicles in cancers.Journal of cancer research and clinical oncology · 2024
    Review
  17. Article
  18. Article
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Taral R LunavatKrefting Research Center, Department of Internal Medicine and Clinical Nutrition, University of Gothenburg, Gothenburg 405 30, Sweden.ORCID 0000-0001-8198-1805
Lesley ChengDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086, Australia.
Berglind O EinarsdottirDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.ORCID 0000-0002-5227-8149
Roger Olofsson BaggeDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.
Somsundar Veppil MuralidharanDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.
Robyn A SharplesDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086, Australia.
Cecilia LässerKrefting Research Center, Department of Internal Medicine and Clinical Nutrition, University of Gothenburg, Gothenburg 405 30, Sweden.
Yong Song GhoDepartment of Life Sciences, Pohang University of Science and Technology, Pohang, Gyeongbuk, 790-784, Republic of Korea.
Andrew F HillDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086, Australia.
Jonas A NilssonDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.
Jan LötvallKrefting Research Center, Department of Internal Medicine and Clinical Nutrition, University of Gothenburg, Gothenburg 405 30, Sweden; jan.lotvall@gu.se.
Sahlgrenska University Hospital · SEThe University of Melbourne · AUUniversity of Gothenburg · SEPohang University of Science and Technology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The BRAF inhibitors vemurafenib and dabrafenib can be used to treat patients with metastatic melanomas harboring

Indexed as

AnimalsCell Line, TumorCutaneous Malignant MelanomaDrug Resistance, NeoplasmExtracellular VesiclesGene Expression Regulation, NeoplasticHumansIndolesMelanomaMice, Inbred NODMicrophthalmia-Associated Transcription FactorMicroRNAsMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSkin NeoplasmsBRAF protein, humanIndolesMicrophthalmia-Associated Transcription FactorMicroRNAsMIRN211 microRNA, humanMITF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSulfonamidesVemurafenibcancerextracellular vesiclesnoncoding RNAssmall RNAs

Identifiers

PMID28684402
PMCPMC5530690
OpenAlexW2725858897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.